Angle Share Discussion Threads

[tbow112] 15/12/2024 21:32

Even £300 is a lot of money if you are proposing that someone should be tested once a month to optimise their treatment. It does seem possible that the system might sell more readily if those costs were brought down.
And given the manifest difficulty of obtaining FDA approval it would never make sense to complicate matters by including reusability in an application, so I am not convinced that the "single-use" specification means very much.
I suspect that I would be quite happy having a cassette with my name on it which could be used for repeat tests.

[millwallfan] 15/12/2024 17:00

From memory whilst the machine cost in the region of £40k the real money spinner was always shown to be the sale and volume of the ‘single use’ cassettes with figures being banded about from £300-£1,000 per test

[bermudashorts] 15/12/2024 16:38

Angle's website is very clear, the cassette is single use only. Indeed, one of the risks picked up by the FDA was that of 'Bloodborne pathogen transmission from blood waste/blood sample' and all data submitted to the FDA and the De Novo approval was on the basis of a single use cassette.

[tbow112] 15/12/2024 15:26

And I suspect it will be easier to clean the cassettes than to clean the machine.

[waterloo01] 15/12/2024 10:09

That's why it takes about 1hr + to run the machine through different cycles to make sure that doesn't happen

[tbow112] 15/12/2024 10:06

And that cannot happen in the machine ?

[waterloo01] 15/12/2024 09:52

Because of the potential of cross contamination.

[tbow112] 15/12/2024 09:37

" cassette that collects blood and captures cancer cells

Sure, let's reuse that"

They reuse the Parsortix machine. What is different about the casette ?

[yasx] 15/12/2024 00:45

Krypton,

I agree deals with other pharma Co’s would be grear, but despite AN being confident in the summer of a couple of deals in 24 with household names nothing happened (other than Recursion which was not what was hoped for). If any such agreements could be crystallised in Q1 that would be a substantial boost.

Perhaps my interpretation of Astra timelines might be overly harsh - but I seem to recall AN hinting at tge next phase being on or around Oct and since then nothing has happened.

I also seem to recall Eisai need is due in Q1 - hopefully early Q1 to iffset any delay in or termination of Astra.

[kryptonsnake] 14/12/2024 19:09

I agree that Angle can't afford to mess things up with Astra

I do not agree that an expansion needs to be announced within weeks

All the data and comms so far point to a successful outcome

Negotiations for the next phase could take some time to complete

I'd like to also see further contracts and deals with new pharma customers taking place early next year



sent from my iPhone

[yasx] 14/12/2024 15:16

Krypton,

Find out in the next few months?

If there is no expansion on the Astra deal within the next few weeks at the latest it then becomes clear that has not gone as expected.

The AZ outcome is key to AGL’s future survival. Without that another raise will be needed by the summer and unless the shares gain traction no raise will be possible.

[kryptonsnake] 14/12/2024 09:14

Yes sales were impacted as mentioned in the half year report

"Product sales have been impacted by the 29 April 2024 announcement by the US Food and Drug Administration (FDA) to regulate laboratory developed tests (LDTs), the initial reaction was muted but has recently led to clinical laboratories cancelling or pausing their new LDT development programmes. In addition, the global slowdown in research funding has worsened and has continued to delay customers' commitment to new contracts"

We also know Angle have switched their strategy to pharma services. We have contracts with Astra etc

This will be a much faster route to mass commercialisation and we will find out if this new strategy is effect or not in the next few months



sent from my iPhone

[yasx] 13/12/2024 22:43

Bobbie,

Yes - they forecast revenues over 6M and came in at a fraction of that.

[bobbie121] 13/12/2024 21:19

Don’t get me wrong I love Parsortix, and its future potential.
What I’m worried about is AN and his marketing skills.
It was quite a while ago when he hired a sales manager and a sales team, do we have any news about sales?

[bobbie121] 13/12/2024 21:05

Krypton,
What have any of the other studies, over the past 10 to 15 years got to do with sales.

[millwallfan] 13/12/2024 20:21

All very interesting and (as always) excellent news for cancer sufferers BUT WE NEED MASS COMMERCIALISATION IN THE SHORT TERM.

[kryptonsnake] 13/12/2024 18:23

A cassette that collects blood and captures cancer cells

Sure, let's reuse that



sent from my iPhone

[gooosed] 13/12/2024 17:55

Bermudashorts - paradigm shifts don't happen instantly, it's the accumulation of evidence that supplants existing established modalities with disruptive (in Angles case also complimentary) technology.

No wonder Andrew Newland felt compelled to attend the San Antonio Breast Cancer Symposium.

[tbow112] 13/12/2024 16:33

Lets try asking again. What stops Parsortix cassettes being reused ?

[kryptonsnake] 13/12/2024 16:09

bobbie

What does a HER2 study have to do with sales?

Use your brain if you've got one



sent from my iPhone

[bobbie121] 13/12/2024 15:22

We must be shifting a lot of machines and cassettes, wow 16 patients.

[5oletrader] 13/12/2024 15:20

Advances in Liquid Biopsy: From exploration to practical applicationhttps://www.linkedin.com/redir/redirect?url=https%3A%2F%2Flnkd%2Ein%2Fe2vNTFxa&urlhash=SiS9&trk=public_post-text-• CTCs are by their nature "FUNCTIONAL BIOMARKERS". Research has indicated that the journey of CTCs through blood circulation is NOT just a PASSIVE shedding but rather an ACTIVE process that SUPPORTS the selection of the "FITTEST" CLONES. Moreover, "MATHEMATICAL MODELING" suggested that the survival of CTCs in the bloodstream seems to be a KEY parameter determining metastatic progression.Interestingly...• MATHEMATICAL MODELING of CTC survival and its role in metastatic progression aligns well with the RECURSION PHARMA partnership - particularly given RECURSIONs focus on leveraging AI, machine learning, and computational biology to understand complex biological systems.• RECURSIONs data-driven approach could help interpret the "FUNCTIONAL ROLE" of CTCs in metastasis, as suggested - MODELING "HOW" CTCs interact with the immune system, evade destruction, and colonise distant sites.https://www.londonstockexchange.com/news-article/AGL/agreement-with-recursion-pharmaceuticals/16673005-• The AIM of PRECISION oncology is to adapt the therapeutic approach according to the LB result, in particular in patients with ADVANCED disease where metastatic tissue is frequently NOT available. In addition, cost, time, morbidity, and mortality CAN be REDUCED compared to when using tissue biopsies. • Despite the OVERWHELMING INTEREST in ctDNA, we strongly believe that a "COMBINATION" of additional LB markers will provide more information than a single marker class, and we are also confident that cellular biomarkers with a "FUNCTIONAL ROLE" in tumor biology (such as CTCs) should NOT BE LEFT BEHIND.• It is widely accepted that LB tests CAN DETECT the progression of a tumor disease MANY MONTHS "BEFORE" imaging.-So...• AGL & PARSORTIX aligns perfectly - enabling real-time, minimally invasive cancer monitoring and precision treatment.By providing "FUNCTIONAL", phenotypically rich biomarkers, AGL addresses critical gaps in tissue biopsies and ctDNA-based LBs, ENSURING ITS RELEVANCE IN "CLINICAL WORKFLOWS" and interventional studies.-Contrast with "PASSIVE BIOMARKERS" - Passive biomarkers (e.g., ctDNA, PSA in prostate cancer):• Reflect static byproducts of the disease, such as CELL DEATH or general tumor burden.• Useful for monitoring and early detection, they DO NOT INFORM about live cellular behavior or active processes.• In essence, "FUNCTIONAL BIOMARKERS" like CTCs offer a window into the "ACTIVE" biology of disease progression, making them especially "VALUABLE" for precision oncology and understanding metastatic dynamics.

[bermudashorts] 13/12/2024 11:20

Yes great RNS, not least because the research was completely independent. Some points worth noting:-

1) The researchers chose to use Parsortix for this study, but some of each sample was also run through CellSearch for comparison. Parsortix isolataed CTCs in 100% of patient samples whereas CellSearch failed to capture any CTCs in approx. 25% of samples.

2) Taking that a stage further, the workflow using Parsortix identified that 38% of all CTCs captured were HER-2 positive versus only 11% of those captured by CellSearch.

3) 33% of the total CTCs captured from patients previously classified as HER-2 negative were found to be HER-2 positive.

Good stuff.

[gooosed] 13/12/2024 10:34

"Dr. Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine, Weill Cornell Medicine commented:

"We are pleased to present further data validating our workflow which enables quantitative and semi-automated assessment of HER2 in CTCs. HER2 is a major therapeutic target and an accurate and real-time assessment of HER2 status could be used to monitor CTCs over time to better guide treatment and identify patients with any detectable HER2 expression, or changes to HER2 expression, who could benefit from treatment with ADCs.

This methodology has the potential to be applied to a wide range of biomarkers and our ultimate goal is to develop automated workflows which enable longitudinal CTC assessment of biomarker status for targeted treatment selection or to predict treatment response."